| Literature DB >> 33826207 |
Pablo Garcia-Pavia1,2,3, Claudio Rapezzi4,5, Yehuda Adler6, Michael Arad7, Cristina Basso3,8, Antonio Brucato9, Ivana Burazor10, Alida L P Caforio3,11, Thibaud Damy12, Urs Eriksson13, Marianna Fontana14, Julian D Gillmore14, Esther Gonzalez-Lopez1,3, Martha Grogan15, Stephane Heymans16,17,18, Massimo Imazio19, Ingrid Kindermann20, Arnt V Kristen21,22, Mathew S Maurer23, Giampaolo Merlini24,25, Antonis Pantazis26, Sabine Pankuweit27, Angelos G Rigopoulos28, Ales Linhart29.
Abstract
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice. © European Society of Cardiology 2021.Entities:
Year: 2021 PMID: 33826207 DOI: 10.1002/ejhf.2140
Source DB: PubMed Journal: Eur J Heart Fail ISSN: 1388-9842 Impact factor: 15.534